Catalent Pharma Solutions has signed a definitive agreement to sell its US commercial packaging operations to a company affiliated with investment group Frazier Healthcare.
The transaction – involving Catalent’s operations based in Philadelphia, Pennsylvania and Woodstock, Illinois – is subject to certain closing conditions and is expected to close in the next few months.
The transaction does not involve Catalent’s Clinical Supply Services operations in Philadelphia, or the Blow-Fill-Seal business in Woodstock; nor does it involve any commercial packaging activity that Catalent conducts outside North America.
The company says the decision to sell its US commercial packaging operations is based on: “The company’s business strategy to focus on growing its world leading businesses in development solutions and advanced delivery technologies, clinical trial supplies, advanced blow/fill/seal aseptic delivery technology for respiratory, ophthalmic and other products, as well as offering integrated solutions for the development and supply of injectable biologics and complex pharmaceutical products.”
Frazier Healthcare was founded in 1991 to invest exclusively in healthcare, and is a leading provider of growth equity and venture capital to high growth and emerging healthcare companies.
Headquartered in Somerset, New Jersey, Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue.
